Amanda L Persons1, Brinda Desai Bradaric2, Leo P Kelly3, Sharanya M Kousik4, Steven M Graves4, Bryan K Yamamoto5, T Celeste Napier6. 1. Department of Pharmacology, Rush University Medical Center, Chicago, IL, 60612, United States; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, 60612, United States; Department of Physician Assistant Studies, Rush University Medical Center, Chicago, IL, 60612, United States; Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, 60612, United States. Electronic address: amanda_l_persons@rush.edu. 2. Department of Pharmacology, Rush University Medical Center, Chicago, IL, 60612, United States; Department of Health Sciences, Rush University Medical Center, Chicago, IL, 60612, United States; Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, 60612, United States. 3. Department of Pharmacology, Rush University Medical Center, Chicago, IL, 60612, United States. 4. Department of Pharmacology, Rush University Medical Center, Chicago, IL, 60612, United States; Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, 60612, United States. 5. Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, 46202, United States. 6. Department of Pharmacology, Rush University Medical Center, Chicago, IL, 60612, United States; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, 60612, United States; Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, 60612, United States.
Abstract
INTRODUCTION: Methamphetamine is a potent psychomotor stimulant, and methamphetamine abusers are up to three times more likely to develop Parkinson's disease (PD) later in life. Prodromal PD may involve gut inflammation and the accumulation of toxic proteins that are transported from the enteric nervous system to the central nervous system to mediate, in part, the degeneration of dopaminergic projections. We hypothesized that self-administration of methamphetamine in rats produces a gut and brain profile that mirrors pre-motor and early-stage PD. METHODS: Rats self-administered methamphetamine in daily 3 h sessions for two weeks. Motor function was assessed before self-administration, during self-administration and throughout the 56 days of forced abstinence. Assays for pathogenic markers (tyrosine hydroxylase, glial fibrillary acidic protein (GFAP), α-synuclein) were conducted on brain and gut tissue collected at one or 56 days after cessation of methamphetamine self-administration. RESULTS: Motor deficits emerged by day 14 of forced abstinence and progressively worsened up to 56 days of forced abstinence. In the pre-motor stage, we observed increased immunoreactivity for GFAP and α-synuclein within the ganglia of the myenteric plexus in the distal colon. Increased α-synuclein was also observed in the substantia nigra pars compacta. At 56 days, GFAP and α-synuclein normalized in the gut, but the accumulation of nigral α-synuclein persisted, and the dorsolateral striatum exhibited a significant loss of tyrosine hydroxylase. CONCLUSION: The pre-motor profile is consistent with gut inflammation and gut/brain α-synuclein accumulation associated with prodromal PD and the eventual development of the neurological disease.
INTRODUCTION: Methamphetamine is a potent psychomotor stimulant, and methamphetamine abusers are up to three times more likely to develop Parkinson's disease (PD) later in life. Prodromal PD may involve gut inflammation and the accumulation of toxic proteins that are transported from the enteric nervous system to the central nervous system to mediate, in part, the degeneration of dopaminergic projections. We hypothesized that self-administration of methamphetamine in rats produces a gut and brain profile that mirrors pre-motor and early-stage PD. METHODS: Rats self-administered methamphetamine in daily 3 h sessions for two weeks. Motor function was assessed before self-administration, during self-administration and throughout the 56 days of forced abstinence. Assays for pathogenic markers (tyrosine hydroxylase, glial fibrillary acidic protein (GFAP), α-synuclein) were conducted on brain and gut tissue collected at one or 56 days after cessation of methamphetamine self-administration. RESULTS: Motor deficits emerged by day 14 of forced abstinence and progressively worsened up to 56 days of forced abstinence. In the pre-motor stage, we observed increased immunoreactivity for GFAP and α-synuclein within the ganglia of the myenteric plexus in the distal colon. Increased α-synuclein was also observed in the substantia nigra pars compacta. At 56 days, GFAP and α-synuclein normalized in the gut, but the accumulation of nigral α-synuclein persisted, and the dorsolateral striatum exhibited a significant loss of tyrosine hydroxylase. CONCLUSION: The pre-motor profile is consistent with gut inflammation and gut/brain α-synuclein accumulation associated with prodromal PD and the eventual development of the neurological disease.
Authors: Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak Journal: Neurobiol Aging Date: 2003 Mar-Apr Impact factor: 4.673
Authors: Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson Journal: Annu Rev Pharmacol Toxicol Date: 2007 Impact factor: 13.820
Authors: Gabrielle Todd; Verity Pearson-Dennett; Robert A Wilcox; Minh T Chau; Kerry Thoirs; Dominic Thewlis; Adam P Vogel; Jason M White Journal: Parkinsonism Relat Disord Date: 2016-02-21 Impact factor: 4.891
Authors: Carmela M Reichel; Lauren A Ramsey; Marek Schwendt; Jacqueline F McGinty; Ronald E See Journal: Neuropharmacology Date: 2011-11-18 Impact factor: 5.250
Authors: Maria G Cersosimo; Gabriela B Raina; Cristina Pecci; Alejandro Pellene; Cristian R Calandra; Cristiam Gutiérrez; Federico E Micheli; Eduardo E Benarroch Journal: J Neurol Date: 2012-12-21 Impact factor: 4.849
Authors: Irina N Krasnova; Margarit Chiflikyan; Zuzana Justinova; Michael T McCoy; Bruce Ladenheim; Subramaniam Jayanthi; Cynthia Quintero; Christie Brannock; Chanel Barnes; Jordan E Adair; Elin Lehrmann; Firas H Kobeissy; Mark S Gold; Kevin G Becker; Steven R Goldberg; Jean Lud Cadet Journal: Neurobiol Dis Date: 2013-05-30 Impact factor: 5.996
Authors: Sandra A Acosta; Naoki Tajiri; Ike de la Pena; Marina Bastawrous; Paul R Sanberg; Yuji Kaneko; Cesar V Borlongan Journal: J Cell Physiol Date: 2015-05 Impact factor: 6.384